Gene-editing startup Tome Biosciences buys Replace Therapeutics
The formal launch of Tome and its buyout of Replace Therapeutics come just as regulators in the US and Europe have approved the first gene-editing drug.
Source: bostonglobe.com
📰 Brucker Corp News
Brucker Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Brucker Corp. Real-time updates on events, politics, business and more.